Advertisement
New Zealand markets closed

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NZD/USD

    0.5892
    -0.0013 (-0.22%)
     

  • NZD/EUR

    0.5523
    -0.0022 (-0.39%)
     

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD

    2,406.70
    +8.70 (+0.36%)
     

  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • NZD/JPY

    91.0710
    -0.1830 (-0.20%)
     

Medtronic gets US clearance for breathing system

FDA OKs Medtronic's Affinity Fusion breathing machine for patients undergoing heart surgery

Associated Press

MINNEAPOLIS (AP) -- Medical device maker Medtronic Inc. said Tuesday it received U.S. clearance for a new artificial lung system that breathes for patients who are undergoing open heart surgery.

The Food and Drug Administration cleared the company's Affinity Fusion oxygenation system, which is designed to oxygenate and remove carbon dioxide from the blood. Each year about 1 million patients worldwide undergo cardiopulmonary bypass surgery, a procedure in which the heart and lungs are temporarily stopped, according to Medtronic.

The device has already been used in surgical procedures at the Cleveland Clinic and the Heart Hospital Baylor Plano, in Plano, Texas.

European regulators approved the Affinity Fusion system last September.

Shares of Medtronic Inc. rose 32 cents to $47.12 in morning trading.